Background. The benefits of continuing antiretroviral therapy are questionable in human immunodeficiency virus (HIV) type 1-infected patients with profound immunodeficiency and multiple treatment failure due to viral resistance.
M A J O R A R T I C L E H I V / A I D S

Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with
Uncontrolled Viral Replication and Profound Immunodeficiency improving immune status [1, 2] . Incomplete virological control is associated with gradual acquisition of antiretroviral-resistant mutations. For patients with multiple treatment failure and a highly resistant viral quasispecies, some experts recommend "gigatherapy"-regimens containing at least 5 or 6 drugs [3, 4] -whereas others proposed temporary treatment discontinuation [4] [5] [6] [7] . The purpose of gigatherapy is to prevent rapid increases in the viral load (VL) and continued depletion of CD4 + cells by maintaining pressure on the viral strain. Treatment interruption is intended to allow wild-type (susceptible) viruses to again become predominant, in the hope that a new treatment will once more be effective when treatment is resumed. Gigatherapy has proven to be partially effective [3] , whereas treatment interruption was found to be beneficial in 1 study [4] but not in others [5] [6] [7] . No clinical study assessed clinical outcome of immunosuppressed patients who stop a failing antiretroviral regimen in comparison with patients who continue it. Indeed, when patients are infected with a highly drug-resistant virus because of failed multiple antiretroviral regimens, have developed profound immunosuppression, and have experienced adverse effects associated with antiretroviral medications, clinicians may question the efficacy of maintaining antiretroviral therapy (ART) or have difficulty finding an optimized treatment regimen. Immunological rather than virological factors may be the main determinants of mid-or long-term HIV disease progression, particularly in patients with very advanced HIV disease [8] [9] [10] [11] [12] [13] [14] . In deeply immunosuppressed patients, no one really knows whether interruption of ART can be proposed with sufficient safety. With use of the French Hospital Database on HIV (FHDH-ANRS CO4), we analyzed patients with a CD4 + cell count !200 cells/mm 3 . Our objective was to compare the risk of clinical progression between patients who continued ART and patients who interrupted ART, mainly among the most immunosuppressed of them.
METHODS
Study Population
The database. The FHDH is a large prospective cohort study of HIV-infected patients who are aged у15 years and have been treated in a network of 68 French university hospitals. The enrollment criteria are documented HIV-1 or HIV-2 infection and written informed consent. Trained research assistants use French Ministry of Health DMI2 software to collect and record, on standardized forms, clinical and biological data at the time of study inclusion and at each visit or hospital admission for an HIV-related clinical event or a new treatment prescription or at least every 6 months.
Patients. To study the impact of maintaining or discontinuing a failing cART regimen on the risk of ADEs, we selected HIV-1-infected patients who were enrolled in the FHDH dur- , had у2 available CD4 + cell count values from follow-up visits, and had received у1 cART regimen (у3 drugs) for у6 months while their CD4 + cell count was !200 cells/mm 3 during the study period. Three groups of patients were compared: the "cART interruption group," which comprised patients with an ARV interruption lasting у3 months and spanning у2 consecutive follow-up visits; the "detectable VL group," which comprised patients with at least 2 consecutive VL values у500 copies/mL while receiving cART; and the "undetectable VL group," which comprised patients with at least 2 consecutive VL values !500 copies/mL while receiving cART. A given patient could thus qualify for all 3 study groups. Patients exposed to IL-2 or hydroxyurea were excluded. Patients prescribed regimens containing delavirdine or enfurvitide were also excluded, because of the small number of patients concerned.
Statistical Analysis
Follow-up data. For each study group, the baseline was defined as the date of the first recorded CD4 + cell count !200 cells/mm 3 after entry into the study group for which the patient qualified. Follow-up data on the cART interruption, detectable VL, and undetectable VL groups were modeled as time-dependent covariates. In each group, all patients' follow-up durations were summed for the calculation of the entire follow-up of the patient in the considered group. Follow-up data were then censored at (1) Definition of clinical events. We estimated the incidence of a new ADE in each group of patients, both overall and in different etiological categories (i.e., viral, fungal, protozoal, bacterial, and "other" infections). Viral events comprised cytomegalovirus disease, herpes simplex virus disease, Kaposi sarcoma, and progressive multifocal leukoencephalopathy. Fungal events comprised esophageal candidiasis, extrapulmonary cryptococcosis, and Pneumocystis jirovecii pneumonia. Protozoal events comprised cerebral or disseminated toxoplasmosis, isosporiasis, and cryptosporidiosis. Bacterial events comprised pulmonary and extrapulmonary tuberculosis, recurrent bacterial pneumonia, recurrent Salmonella sepsis, and atypical mycobacteriosis. "Other" events comprised HIV encephalopathy, invasive cervical cancer, non-Hodgkin lymphoma, and primary brain lymphoma.
Statistical methods. The incidence rates (IRs) of new ADEs in each group of patients were calculated by dividing the number of patients who had a new ADE during the entire followup period as part of the considered group by the number of person-years (PYs) at risk in the considered group, both overall and within the 2 CD4 + cell count strata (!50 and 50-200 cells/ mm 3 ). When the occurrence of a new ADE among each group of patients was analyzed, only the first ADE in the patient's follow-up was considered. When ADE occurrence within each etiological category was analyzed, the first specific event within each category was considered. For instance, a patient who had both cytomegalovirus disease and Kaposi sarcoma during his or her follow-up was considered to have only 1 viral event for the calculation of the IR for viral events, whereas an individual who experienced events in у2 different etiologic categories was counted once in each category.
Factors associated with the risk of a new ADE were assessed by using univariate and multivariate analyses (Cox's proportional-hazards models with counting process) [15] . This extension includes time-dependent strata and left truncation of failure times. In our analysis, the time-dependent strata were the 3 groups of patients. ), prophylaxis for P. jirovecii pneumonia and/or toxoplasmosis, and the study group. All variables associated with the risk of a new ADE in univariate analysis were included in the multivariate model (sex, HIV transmission group, calendar period of inclusion, CD4 + cell count stratum, baseline VL stratum, prophylaxis against P. jirovecii pneumonia or toxoplasmosis, and the study group). All tests were 2-sided, and P values !.05 were considered to be statistical significant. All statistical analyses were performed using SAS software package, version 8 (SAS Institute). An adapted version of the PROC PHREG procedure was used for the counting-process formulation of the Cox model.
RESULTS
Baseline Characteristics
During 2000-2005, 12,765 patients (72.2% men) were selected. Table 1 describes the patients' baseline characteristics at the date of their first qualification in each study group and their subsequent follow-up in the study group.
At baseline, 6703 patients (52.5%) received PI-containing cART, mainly ritonavir-boosted PI (3225 patients), nelfinavir (2047 patients), and indinavir (1501 patients); 3533 patients (27.7%) received a nonnucleoside reverse-transcriptase inhibitor-containing regimen (nevirapine for 1466 patients and efavirenz for 2065 patients); and 2529 (19.8%) received a triplenucleoside reverse-transcriptase inhibitor regimen only. Each patient could receive у1 regimen during his or her follow-up treatment. The cART-interruption group comprised 2399 patients who had at least 1 cART interruption (of whom 38.7% had a baseline VL 130,000 copies/mL). The detectable-VL group comprised 8783 patients (of whom 45.5% had a baseline VL 130,000 copies/mL). The undetectable-VL group comprised 6548 patients. Overall, 4351 patients (34.1%) participated in 
Clinical Progression
Frequency of clinical events. Table 2 shows the IRs for new ADEs in each group, both overall and according to the CD4 + cell count stratum and the type of event. During the period, 348 patients with cART interruption had an ADE during a total follow-up of 1880 PYs (IR, 18.5 cases per 100 PYs), with 99 ADEs (28.4%) occurring during the first month of cART interruption; 1483 patients with detectable VL had an ADE during a follow-up of 10,263 PYs (IR, 14.5 cases per 100 PYs), with 189 (12.8%) occurring during the first month of inclusion in the detectable group; and 310 patients with undetectable VL had an ADE during a follow-up of 6324 PYs (IR, 4.9 cases per 100 PYs), with 59 (19.0%) occurring during the first month of inclusion in the undetectable group. Overall, the IRs were lower in the detectable VL group than in the cART-interruption group and were lower still in the undetectable VL group.
Within each group, the IRs for new ADEs were higher in the !50 cells/mm 3 CD4 + cell count stratum than in the 50-200 cells/mm 3 stratum. Among both CD4 + cell count strata, the ADE IRs were lower in the detectable VL group than in the cART-interruption group and were lower still in the undetectable VL group. ADE IRs were significantly higher in patients with baseline VL 130,000 copies/mL than in patients with lower baseline VL values, both among patients with treatment interruption (IR, 24 Description of clinical events. The most common events in patients with cART interruption and in patients with detectable VL were esophageal candidiasis (29.9% and 23.3%, respectively), P. jirovecii pneumonia (16.1% and 15.0%, respectively), toxoplasmosis (14.4% and 13.5%, respectively), cytomegalovirus disease (12.4% and 14.1%, respectively), and tuberculosis (13.5% and 9.4%, respectively); in patients with undetectable VL, the most frequent events were tuberculosis (19.0%), Kaposi's sarcoma (15.2%), non-Hodgkin lymphoma (12.3%), and esophageal candidiasis (10.6%). The main first events were fungal infections (38.4% and 32.9%, respectively) in patients with cART interruption and in patients with detectable VL and were bacterial infections (30.4%) in patients with undetectable VL. Figure 1 shows the IRs of the most frequent ADEs in each group of patients and the associated P values relative to the cART interruption group, in adjusted Cox models. For all events, IRs were significantly lower in patients with detectable VL and in patients with undetectable VL than in patients with cART interruption.
Risk analyses. Table 3 shows the estimated risks (i.e., hazard ratios) for a new ADEs, according to the CD4 + cell count NOTE. Values-calculated using Cox proportional-hazards models with counting process, adjusted for sex, HIV transmission group, prophylaxis against Pneumocystis jirovecii pneumonia or toxoplasmosis, the baseline VL stratum, and the calendar period of inclusion-are overall and according to the CD4 + cell count stratum and the etiological category. cART, combination antiretroviral therapy; VL, viral load.
stratum and the type of event, with the cART-interruption group as reference, after adjustment for sex, the HIV transmission group, prophylaxis for P. jirovecii pneumonia or toxoplasmosis, the CD4 + cell count, the baseline VL stratum, and the calendar period of inclusion.
Overall, the risk of a new ADE was 22% and 62% lower in patients with detectable VL and in patients with undetectable VL on cART, respectively, than in patients with cART interruption.
Among patients with a CD4 + cell count !50 cells/mm 3 and among patients with a CD4 + cell count of 50-200 cells/mm 3 , the 2 cART-treated groups (detectable and undetectable VL) had a significantly lower risk of new ADEs than did patients with treatment interruption (hazard ratio, 0.78 and 0.48, respectively, for patients with CD4
+ cell count !50 cells/mm 3 ; hazard ratio, 0.66 and 0.27, respectively, for patients with a CD4 + cell count of 50-200 cells/mm 3 ). When patients whose follow-up was !1 month in the study group were excluded from the analysis, results were similar (table 3) .
DISCUSSION
Patients with detectable VL who continued ARV therapy had lower IRs and risks of ADEs of all types than did patients who stopped their treatment, both in the overall population and after CD4 + cell count stratification. The patients with the lowest IRs and risks of ADE were those with undetectable VL while on cART.
Several recent studies have examined whether ART can safely be discontinued in patients with a CD4 + cell count у350 cells/ mm 3 [16] [17] [18] [19] . A low nadir CD4 + cell count was the best predictor of clinical events (ADEs or death) and the subsequent decrease in the CD4 + cell count [19] . When ART was resumed at a CD4 + cell count !250 cells/mm 3 , the incidence of clinical events, ADE, or death was significantly increased, and the relative risk of disease progression or death was significantly higher than in patients who continued ART [17] [18] . The risk of opportunistic infections increases significantly at CD4 + cell count below the classic threshold of 200 cells/mm 3 , and such patients require prompt ART plus prophylaxis for P. jirovecii pneumonia and toxoplasmosis. ARV withdrawal for 8-24 weeks has been assessed in highly ARV-experienced patients with low CD4 + cell count, but the risk of disease progression or death was higher, and the decrease in the CD4 + cell count was sharper than in patients who continued ART [5] [6] [7] . Other cohort studies have suggested that treatment interruption has a negative impact on the prognosis of highly ARV-experienced patients [12, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] , particularly among the most immunodeficient patients [21] [22] [23] , but no study compared clinical outcome of deeply immunosuppressed patients who interrupted with those who continued while the CD4 + cell count was !50 cells/mm replication, after adjustment for the CD4 + cell count, AIDS status, and ART [12, 21, 22, 24] . This also argues for the maintenance of ART in such patients.
No resistance data were available in this study, and we did not analyze the reasons for cART interruption. Data on reasons for treatment interruptions are not collected in the FHDH database. Reasons can be in poor compliance because of psychosocial factors, adverse effects of the medications, progressive disease with symptoms of sickness, and weariness of the treatment leading to an interruption of the cART. Analyses of IRs and hazard ratios for new ADE after exclusion of patients with a follow-up !1 month had results similar to those of the analysis of all the study population. Therefore, if some patients in the cART interruption group were sicker than patients in the detectable VL group, in spite of similar CD4 + cell counts, and if they stopped taking their treatment because of progressive disease, indication biases because of such patients were taken into account by these models. Furthermore, multivariable models were adjusted for baseline VL strata and CD4 + cell count strata during follow-up. At the date of inclusion in the groups, ∼25% of the patients had no prophylaxis against P. jirovecii pneumonia or toxoplasmosis, despite a CD4 + cell count !200 cells/ mm 3 . This argues for a weariness of the treatment. Prophylaxis at the date of inclusion in each group was not compared among the different groups, but multivariable models were adjusted on prophylaxis against P. jirovecii pneumonia or toxoplasmosis during the follow-up as a time-dependant variable, and effect of interruption of prophylaxis on ADE occurrence was taken into account. Because very few patients were receiving atypical mycobacteriosis prophylaxis and because French guidelines recommended a focus on ART and prophylaxis against P. jirovecii pneumonia and toxoplasmosis in such patients, during the study period, models were not adjusted for atypical mycobacteriosis prophylaxis. Observational databases like the FHDH, which include substantial numbers of patients managed in numerous hospitals, can explore clinical events that may be too infrequent to assess in clinical trials. Moreover, in profoundly immunodeficient patients, randomized trials of treatment interruption versus treatment continuation may be ethically unacceptable.
Several observations suggest that drug-resistant strains of HIV-1 are less fit than their wild-type counterparts [25] . This might partly explain why reversion to a wild-type quasispecies after treatment interruption appears to be deleterious [25, 26] . Maintenance of a failing drug regimen to which the patient's HIV quasispecies is resistant may still interfere with viral replication and thereby slow the immunological and clinical deterioration [27] . Furthermore, that antiretroviral treatment might have beneficial effects mediated by mechanisms other than the CD4 + cell increment or the reduction in VL, as previously suggested [12, 21, 28] . Indeed, these surrogate markers do not always accurately predict the clinical efficacy of ART [29] [30] [31] . Thus, the predictive value of CD4 + cell count and HIV RNA level may be different in patients off therapy than in patients on therapy [27] [28] [29] [30] [31] [32] . Persistently low viral replication (200-10,000 copies/mL) during ART stimulates higher frequencies of HIV-specific CD4 + and CD8 T cells, compared with full virus suppression or complete ART failure [32] . Some authors have suggested that drug-resistant HIV-1 may be less pathogenic than wild-type virus and that continued use of cART might provide a clinical benefit, despite persistent viremia and drug resistance [33] . Immune defenses against other pathogens are also preserved in patients with persistent low-level HIV replication, because lymphoproliferative responses to recall antigens are similar in patients with low VL and in patients with undetectable VL and are different in patients with high VL [32] . This is supported by our results showing that patients who discontinued cART had a higher incidence of ADEs than did patients with detectable VL on cART. In conclusion, our results suggest that, when profoundly immunodeficient HIVinfected patients have no further treatment options permitting effective viral control, maintaining a failing regimen is preferable to interrupting it.
